Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by tylerreddickon Nov 07, 2024 10:30am
74 Views
Post# 36300984

RE:RE:RE:RE:Over 450,000 shares traded now

RE:RE:RE:RE:Over 450,000 shares traded nowSBM reminds me of another Vulture exchange stock I followed for a while, They too issued all kinds of promising news releases (although the other stock's CEO actually outright lied), and nothing ever came of anything.
So far, SBM is following the same path.
If they don't follow through on the GPM promises, then management is getting far too close to lying for my taste.

But this statement:
" We are carefully assessing the most favorable markets for the initial launch to ensure long-term success. Our internal analysis, grounded in market data, suggests that a successful launch in just one key region could bring Sirona to profitability as early as 2025. "

Add this recent twitter statement:

Sirona Biochem is exploring expansion of its anti-aging compound TFC-1326 into South Korea, driven by strong interest post-GREDECO study. This move boosts market reach, opens doors for Korean partnerships, and fuels sustainable growth

And it would appear that South Korea is that "most favorable market for the initial launch"

I guess time will tell.
<< Previous
Bullboard Posts
Next >>